Cancer stem cell assay-guided chemotherapy improves survival of patients with recurrent glioblastoma in a randomized trial.
ChemoID
assay-guided chemotherapy
cancer stem cells
chemotherapy
drug response assay
functional assay
glioblastoma
overall survival
personalized medicine
recurrent glioblastoma
Journal
Cell reports. Medicine
ISSN: 2666-3791
Titre abrégé: Cell Rep Med
Pays: United States
ID NLM: 101766894
Informations de publication
Date de publication:
16 05 2023
16 05 2023
Historique:
received:
14
09
2022
revised:
19
12
2022
accepted:
10
04
2023
medline:
19
5
2023
pubmed:
4
5
2023
entrez:
3
5
2023
Statut:
ppublish
Résumé
Therapy-resistant cancer stem cells (CSCs) contribute to the poor clinical outcomes of patients with recurrent glioblastoma (rGBM) who fail standard of care (SOC) therapy. ChemoID is a clinically validated assay for identifying CSC-targeted cytotoxic therapies in solid tumors. In a randomized clinical trial (NCT03632135), the ChemoID assay, a personalized approach for selecting the most effective treatment from FDA-approved chemotherapies, improves the survival of patients with rGBM (2016 WHO classification) over physician-chosen chemotherapy. In the ChemoID assay-guided group, median survival is 12.5 months (95% confidence interval [CI], 10.2-14.7) compared with 9 months (95% CI, 4.2-13.8) in the physician-choice group (p = 0.010) as per interim efficacy analysis. The ChemoID assay-guided group has a significantly lower risk of death (hazard ratio [HR] = 0.44; 95% CI, 0.24-0.81; p = 0.008). Results of this study offer a promising way to provide more affordable treatment for patients with rGBM in lower socioeconomic groups in the US and around the world.
Identifiants
pubmed: 37137304
pii: S2666-3791(23)00135-0
doi: 10.1016/j.xcrm.2023.101025
pmc: PMC10213810
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Types de publication
Randomized Controlled Trial
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
101025Subventions
Organisme : NIGMS NIH HHS
ID : U54 GM115428
Pays : United States
Organisme : NIGMS NIH HHS
ID : P20 GM121334
Pays : United States
Informations de copyright
Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests P.P.C. and J.V. report ownership of intellectual property rights on the CSC platform technology licensed to Cordgenics, LLC.
Références
Clin Cancer Res. 2007 Feb 15;13(4):1253-9
pubmed: 17317837
JCI Insight. 2021 Feb 22;6(4):
pubmed: 33400685
JAMA Oncol. 2020 Jul 1;6(7):1003-1010
pubmed: 32437507
BMC Med Res Methodol. 2013 Dec 07;13:152
pubmed: 24314264
J Neurooncol. 2012 Apr;107(2):359-64
pubmed: 22045118
Lancet Oncol. 2009 May;10(5):459-66
pubmed: 19269895
JAMA. 2013 Nov 6;310(17):1842-50
pubmed: 24193082
PLoS One. 2014 Aug 21;9(8):e105710
pubmed: 25144312
Neuro Oncol. 2021 Aug 2;23(8):1231-1251
pubmed: 34185076
CNS Oncol. 2019 Mar 1;8(1):CNS28
pubmed: 30806082
Transl Oncol. 2020 Apr;13(4):100755
pubmed: 32197147
J Clin Oncol. 2009 Oct 1;27(28):4733-40
pubmed: 19720927
Nature. 2012 Aug 23;488(7412):522-6
pubmed: 22854781
Gastrointest Cancer Res. 2008 Jul;2(4):169-74
pubmed: 19259284
Nat Commun. 2019 Apr 16;10(1):1787
pubmed: 30992437
J Clin Oncol. 2007 Oct 20;25(30):4722-9
pubmed: 17947719
Cancer Res. 2015 Mar 15;75(6):924-9
pubmed: 25604264
Transl Oncol. 2017 Apr;10(2):241-254
pubmed: 28199863
CA Cancer J Clin. 2022 Mar;72(2):112-143
pubmed: 34878180
Ann Oncol. 2018 Jun 1;29(6):1431-1436
pubmed: 29617713
Nat Med. 2017 Oct 6;23(10):1124-1134
pubmed: 28985214
PLoS One. 2010 Apr 08;5(4):e10035
pubmed: 20386701
Neuro Oncol. 2021 Mar 25;23(3):502-503
pubmed: 33471898
CA Cancer J Clin. 2022 Mar;72(2):144-164
pubmed: 34751943
Lancet Oncol. 2017 Jun;18(6):e315-e329
pubmed: 28483413
J Clin Oncol. 2010 Apr 10;28(11):1963-72
pubmed: 20231676
Transl Oncol. 2020 Dec;13(12):100860
pubmed: 32862103
Neuro Oncol. 2013 Jan;15(1):4-27
pubmed: 23136223
Neuro Oncol. 2022 Nov 2;24(11):2001-2004
pubmed: 35906902
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
Genes Dev. 2015 Jun 15;29(12):1203-17
pubmed: 26109046